march
world
health
organ
declar
corona
viru
pandem
march
outbreak
confirm
around
countri
world
health
organ
far
infect
peopl
worldwid
caus
death
context
sever
affect
countri
unit
state
america
usa
itali
spain
china
vaccin
approv
target
drug
treatment
still
unknown
current
manag
support
world
health
organ
morbid
mortal
associ
respiratori
failur
due
acut
respiratori
distress
syndrom
ard
world
health
organ
chen
et
al
addit
complic
also
relat
elderli
age
comorbid
heart
diseas
diabet
mellitu
cancer
smoke
habit
lung
diseas
asthma
chronic
obstruct
pulmonari
diseas
among
other
world
health
organ
context
concern
whether
immunosuppress
ist
treatment
increas
risk
sever
current
evid
patient
ist
treatment
recent
transplant
patient
higher
risk
complic
therefor
evid
vulner
popul
may
trigger
dysregul
balanc
lymphocyt
demonstr
may
primarili
involv
lymphocyt
particularli
diminish
cell
chen
et
al
addit
b
cell
level
significantli
high
sever
case
chen
et
al
howev
recent
publish
patient
sever
may
experi
cytokin
storm
syndrom
css
hyperinflammatori
respons
viru
mainli
relat
monocytemacrophag
system
activ
mehta
et
al
typic
hyperactiv
describ
context
celldirect
ist
treatment
chen
et
al
mehta
et
al
recent
report
increas
interleukin
il
level
pneumonia
risk
factor
mortal
chines
cohort
n
infect
chines
clinic
trial
registri
elev
concentr
cell
associ
overactiv
cell
could
contribut
sever
complic
xu
et
al
elev
proinflammatori
cytokin
also
describ
sever
case
biomark
ddimer
ferritin
associ
sever
mehta
et
al
neuromyel
optica
spectrum
disord
nmosd
defin
astrocytopathi
often
character
devast
neurolog
sequela
includ
persist
paraplegia
blind
nmosd
increas
risk
present
time
evid
suggest
nmosd
increas
risk
develop
sever
would
increas
risk
nmosd
relaps
although
wellknown
infect
may
trigger
relaps
particularli
viral
infect
evid
caus
exacerb
nmosd
patient
relaps
confirm
patient
need
steroid
treatment
use
steroid
infect
patient
remain
controversi
world
health
organ
howev
new
clinic
trial
recent
initi
compar
iv
methylprednisolon
mgkgday
day
versu
control
group
without
steroid
patient
sever
novel
coronaviru
pneumonia
help
respons
question
near
futur
clinicaltrialsgov
identifi
sinc
disabl
nmosd
relapserel
palac
et
al
longterm
relaps
prevent
treatment
recommend
posit
neg
patient
diagnos
nmosd
azathioprin
mycophenol
mofetil
rituximab
wide
use
drug
treat
nmosd
collongu
et
al
recent
placebocontrol
trial
nmosd
treatment
publish
pittock
et
al
cree
et
al
tahara
et
al
monoclon
antibodi
eculizumab
anti
complement
protein
pittock
et
al
inebilizumab
cree
et
al
rituximab
tahara
et
al
satralizumab
receptor
yamamura
et
al
shown
reduc
risk
new
relaps
compar
placebo
addit
random
openlabel
headtohead
studi
tango
zhang
et
al
compar
intraven
tocilizumab
inhibitor
versu
azathioprin
show
tocilizumab
significantli
reduc
relaps
stabil
nmosd
patient
continu
treat
nmosd
patient
ist
therapi
pandem
evid
stop
ist
treatment
decreas
risk
sever
previous
mention
sever
may
associ
css
strikingli
two
drug
use
treat
nmosd
current
evalu
confirm
infect
patient
intraven
iv
tocilizumab
random
doubleblind
placebocontrol
phase
iii
clinic
trial
evalu
safeti
efficaci
plu
standard
care
hospit
adult
patient
sever
pneumonia
clinicaltrialsgov
identifi
eculizumab
confirm
infect
patient
ard
icu
patient
clinicaltrialsgov
identifi
prophylact
therapeut
measur
recommend
immun
particularli
influenza
vaccin
pneumococc
vaccin
varicella
zoster
viru
vaccin
includ
vaccin
schedul
import
addit
gener
recommend
hygien
quit
smoke
social
distanc
among
other
best
practic
mitig
risk
infect
world
health
organ
although
evidencebas
data
present
time
tocilizumab
eculizumab
rituximab
may
use
highli
activ
nmosd
individu
case
need
risksbenefit
assess
addit
data
cours
nmosd
patient
receiv
ist
treatment
recommend
exist
stop
treatment
use
nmosd
patient
far
pandem
unfold
worldwid
demand
data
impact
novel
coronaviru
nmosd
patient
grow
rapidli
inform
crucial
patient
clinician
make
evidencebas
decis
manag
diseas
pandem
case
acquir
guidelin
clinician
manag
treat
nmosd
patient
need
none
author
potenti
financi
conflict
interest
relat
manuscript
research
receiv
specif
grant
